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The primary causes of death in the United
States are heart disease/stroke (864,000
deaths in 1990) and lung cancer (141,000
deaths in 1990) (1). In addition to the
obvious effects on the victims and their
families, the costs of these diseases are very
high in terms of lowered productivity,
increased costs, and added stress to the
health care system. The very strong associa-
tion of smoking with these diseases is par-
ticularly striking. Nearly 90% of all lung
cancers are attributible to cigarette smok-
ing, and smoking is also associated with
cancers at a number ofother sites, including
the mouth, larynx, pancreas, and bladder
(2). The incidence ofcoronary heart disease
is twice as high among smokers as non-
smokers and four times higher for heavy
smokers as nonsmokers. In addition, death
rates from coronary heart disease are 70%
higher for smokers and more than twice as
high for heavy smokers than for nonsmok-
ers (3).
The deleterious health effects associated
with smoking arise from two main
sources-mainstream smoke and environ-
mental tobacco smoke (ETS; second-hand
smoke; passive smoke). Mainstream smoke,
which emerges from the mouth end of a
cigarette, is the primary source of harmful
agents to smokers. Eighty-five to 90% of
ETS comes from aged and diluted side-
stream smoke (from the burning end of a
cigarette), with the remainder coming
from exhaled mainstream smoke. In recent
years there has been a great increase in
public sensitivity to the perceived, poten-
tially harmful effects of ETS exposure on
nonsmokers. Epidemiological studies have
lent support to these perceptions. The U.S.
Environmental Protection Agency (EPA)
has classified sidestream smoke as a human
carcinogen and has attributed -3,000
excess lung cancer deaths in the United
States each year to involuntary exposure to
ETS (4). A role for ETS in the appearance
of precancerous lung lesions has also been
reported (5). The effects of ETS on car-
diovascular disease are estimated to be far
more extensive. The American Heart
Association has recommended that ETS be
classified as a major environmental toxin
and has classified ETS as a major pre-
ventable cause of heart disease (6). In a
recent review (7), it was estimated that
>60,000 excess preventable heart disease
deaths occur yearly in the United States
due to involuntary exposure to ETS. Two
recent studies from our laboratory provid-
ed direct experimental support for this
contention. Results from studies using the
cockerel model of arteriosclerotic plaque
development (8,9) revealed that inhalation
exposure to ETS at levels equal to or even
below those that can be encountered by
people in smoke-filled environments is suf-
ficient to promote arteriosclerosis (10,11).
Atherosclerosis studies in cholesterol-fed,
smoke-exposed rabbits confirm these find-
ings (12).
Many ofthe same chemicals are present
in mainstream smoke and ETS, although
their relative abundances in the two smoke
fractions are different (13). Despite the
overwhelming evidence implicating ciga-
rette smoke (CS) in the development of
both cardiovascular disease and lung cancer,
it has been virtually impossible to identify a
single component of CS that, at environ-
mentally relevant levels, is responsible for
any of the observed health effects. The
major reason is that although more than
4,500 compounds, many of which can be
cytotoxic or carcinogenic, have been identi-
fied in CS (13), most are present in concen-
trations deemed to be too low to be effec-
tive individually. Polynuclear aromatic
hydrocarbon (PAH) carcinogens, e.g.,
benzo(a)pyrene [B(a)P], and nitrosamines
in the tar fraction are considered primarily
responsible for the effects of CS on lung
cancer and heart disease. Indeed, these and
related compounds are effective at inducing
or promoting these diseases experimentally,
but only when administered at levels many
times (often orders of magnitude) higher
than the levels at which they are found in
mainstream smoke or in ETS (14-22).
Recently, we reported results of a study
in which we tested the effects of two CS
components on arteriosclerotic plaque devel-
opment in cockerels (23). The tar fraction
nitrosamine 4-(n-methyl-n-nitrosamino)-1-
(3-pyridyl)-1-butanone (NNK), which is
carcinogenic at high concentrations in
rodents (14,18), had no effect on plaque
development in cockerels when injected
biweekly at doses of 10 mg/kg. The injection
protocol we followed is effective at demon-
strating the plaque-promoting effects of a
variety of chemicals and environmental
agents (16,19). However, inhalation expo-
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sures to the volatile alkene 1,3 butadiene, a
vapor phase component ofboth mainstream
smoke and ETS, effectively promoted
plaque development at doses (20 ppm) only
2 times higher than the threshold limit value
(TLV) at the time ofthe experiments. (The
8-hr time-weighted average TLV for 1,3
butadiene has recently been reduced from 10
ppm to 2 ppm). These results suggest thatthe
plaque-promoting components ofCS reside
mainly in the vapor phase. To test this sug-
gestion, we carried out the plaque-promotion
experiments described here. We injected
either solubilized concentrated tar or a PAH
carcinogen, 7,12 dimethylbenz(a)anthracene
(DMBA), into cockerels. As expected, based
on previous plaque development studies
with carcinogens (15,16,19,24), DMBA
was a strong promoter of plaque develop-
ment; however, the solubilized CS tar was
totally ineffective. These findings support
the conclusion that the major arteriosclerot-
ic plaque-promoting components of CS
reside in the vapor phase rather than in the
tarfraction.
Materials and Methods
Two- to 3-week-old white leghorn chicks
(Hyline International, Dallas Center, IA)
were quarantined for 2 weeks, during
which time they were acclimated to a 12 hr
light/dark cycle and observed for anom-
alous behavior and disease. As in our previ-
ous studies, only males were used.
Cockerels were distributed randomly into
three groups of 10 each and were housed in
stainless steel dog cages (2-4/cage). Care
and treatment were in accordance with
established guidelines. Cockerels received
food (Chick Starter Grower, Purina, St.
Louis, MO) and water ad libitum. They
were weighed weekly and their health was
monitored daily. Exposures began at 5
weeks ofage.
Tar was extracted in a well-ventilated
hood from 20 2R1 unfiltered reference ciga-
rettes at a time (Tobacco and Health
Research Institute, University of Kentucky,
Lexington, KY). An all-glass smoking
machine was used; this machine consisted of
a cylinder in which the tobacco was burned
connected to a series ofeight tubes cooled to
-400 C by an alcohol-dry ice bath (25). The
tubes were connected with ground glass
joints. Each tube was filled with 20 ml of
acetone. A 75 cc volume of air was drawn
through the smoking system (1itimes per
minute) by a Palmer respiration pump
(Fisher, Valley Forge, PA). The temperature
of the burning tobacco ranged from
5000-700° F. The crude tar fractions col-
lected from each of the tubes were pooled
and stirred overnight at room temperature.
The crude tar was resuspended in acetone,
aliquoted, and frozen until use. The acetone
was evaporated before the tarwas solubiized
in dimethylsulfoxide (DMSO, Fisher, Valley
Forge, PA). The extraction process yielded
-850 mg of tar per pack. The tar was pre-
pared fresh monthly. (The tar tested here is
more rigorously dassified as cigarette smoke
condensate, since it is collected in a cold
trap; however, for purposes ofsimplicity we
will refer to it as TAR). Cockerels were
injected weekly (intramuscularly; im)
according to our standard protocols
(16,19). The tar dose was 25 mg/kg/week
and the DMBA dose (Sigma, St. Louis,
MO) was 10 mg/kg/week. Tar and DMBA
were solubilized in DMSO. Control cock-
erels were injected with 1 ml DMSO/
kg/week. All animals were sacrificed
humanely at 21 weeks ofage after receiving
16 weekly injections each. Aortas were
opened longitudinally, rinsed with saline,
and fixed in 10% buffered formalin. Aortas
were sectioned transversely at 5-6 mm inter-
vals from the ischiatic bifurcation to the tho-
racic aorta (nine sections per cockerel).
Following paraffin embedding, 5 pm thick
sections were cut from the distal face ofeach
block. Sections were exposed to theVerhoff-
van Gieson stain (26) to distinguish plaque
from underlying arterywall and to stain col-
lagen (red) and elastin (black). The cross-
sectional areas of plaques present in each
plaque-containing segment were measured
microscopically, as described previously
(16,19), i.e., maximal depth x width of
plaques. All segments with visible plaque
were scored. When a consecutive group of
plaque-containing segments within an aorta
was broken by a segment with no visible
plaque, the aorta was scored as having two
plaques. All samples were coded prior to
analysis.
StatisticalAnalysis
The number of plaques per cockerel and
the numbers of plaque-containing seg-
ments per cockerel in the three groups were
each compared by ANOVA. Plaque sizes,
which were log-normally distributed, were
log-transformed for statistical evaluation.
The dependence of plaque size both on
location along the aorta and on treatment
was determined by a 2-factor ANOVA
using the SuperANOVA program (Abacus
Concepts, Berkeley, CA). Least squares
analysis was used to compare plaque size
for any segment among the three groups.
Results
There were 10 cockerels in each group at the
start ofthe experiment. One cockerel in the
DMSO group died in the fourteenth week
of the study and was not included in the
data analysis. There were no significant dif-
Table 1. Effect of treatments with DMBA, ciga-
rette tar (TAR), or DMSO on plaque prevalence in
cockerel aortas
Plaque
No. Plaques/ segments/
cockerels cockerela cockerel8
DMSO 9 1.44± 0.17 8.11± 0.23
DMBA 10 1.30 ± 0.15 7.40 ± 0.35
TAR 10 1.70 ± 0.20 7.40± 0.21
aAll values are mean ± SEM.
ferences in body weights between cockerels
in any ofthe groups at any time point (data
not shown). All major organs appeared
grosslynormal at autopsy.
There was no significant effect of treat-
ment on the number ofplaques per cockerel
(1.3-1.7) or on the number of aortic seg-
ments (7.4-8.1) with measurable plaque per
cockerel (Table 1). There were 73 segments
with plaque in the DMSO group and 74
each in the DMBA and TAR groups. As
reported previously (9-11,16,19) plaque
sizes were log-normally distributed, i.e.,
mean plaque sizes exceeded medianvalues in
all three groups (data notshown).
Both treatment and location were associ-
ated with a significant increase in plaque size
within each group ofcockerels. Figure 1 dis-
plays the association oflocation with plaque
size for abdominal aorta segments from all
the cockerels in each of the three groups.
The largest plaque sizes are found in the
three most distal segments ofthe abdominal
aorta, regardless of treatment. The effect of
treatment on plaque size is shown in Figure
2. As expected, DMBA treatment resulted in
asignificant increase in plaque size compared
to both TAR and DMSO (F = 4.84; p =
0.009). In contrast, TAR treatments had no
significant effect on plaque size. In fact, the
effects of TAR and DMSO were indistin-
guishable. When the effects oftreatment and
location were combined, the aortic segments
with the largest plaques were segments 1 and
3 in the DMBA group. Plaque sizes in these
segments were significantlylarger than in the
same segments in the TAR (p = 0.05; 0.026)
and DMSO (p = 0.002; 0.015) groups
(Table 2). When DMSO and TAR groups
were compared, therewere no significant dif-
ferences in plaque size for any aortic seg-
ment. Thus, weekly injections ofconcentrat-
ed cigarette tar into cockerels, according to a
protocol that has been used successfully to
identify arteriosclerotic plaque-promoting
agents in the environment, were without
effect onplaque promotion.
Discussion
The data supporting a role for cigarette
smoking in lung cancer (and other cancers)
and in heart disease are overwhelming. The
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Figure 1. Relationship between size and location of arteriosclerotic plaques in the abdominal aortas of
cockerels. The means of the log-normally distributed plaque sizes are shown for the six most distal con-
tiguous segments of the abdominal aorta. For DMSO, n = 9, and for OMBA and TAR, n = 10. The results
show that treatment did not alter plaque location and that the largest plaque sizes were found in the most
distal segments of the aorta, regardless of treatment.
association of smoking with lung cancer
was clearly established over 40 years ago
(27-29), and the association of smoking
with heart disease was recognized by the
U.S. Surgeon General over 30 years ago
(30). It is widely assumed that tar fraction
components ofcigarette smoke-especially
the PAH carcinogens (e.g., B(a)P) and
nitrosamines (e.g., NNK)-are primarily
responsible for these profound health
effects (14,17,18,20-22,31-37). The
results presented here combined with oth-
ers we have recently published (23) demon-
strate that, at least as far as heart disease is
concerned, this assumption should be reex-
amined. The results here show clearly that
repeated injections of concentrated solu-
tions of tar from burning unfiltered ciga-
rettes have no effect on the development of
arteriosclerosis in a sensitive model of the
disease. Cockerels are sensitive to plaque-
promoting effects ofcertain environmental
contaminants whether they are adminis-
tered by injection (15,16,19,23), as was the
case here, or by inhalation (10,11,23,38).
There are two characteristics ofthis ani-
mal model of arteriosclerosis that make it
particularly valuable for studies of the type
described here. The first is that chickens
develop naturally occuring fibromuscular
arteriosclerotic plaques that appear sponta-
neously in the abdominal aorta (8). In the
absence of exogenous stimuli, these sponta-
neous plaques remain microscopic for most
of the first year of life (9,24). They are
probably a form ofthe intimal cell masses or
intimal pads that have been described as
sites of focal intimal proliferation in both
young humans and young animals (39-42).
The second characteristic is that both main-
stream (38) and sidestream (10,11) CS, as
well as some carcinogens present in CS
(15,16,19,24), stimulate development of
these spontaneous plaques, whereas other
tobacco components including the tobacco-
specific nitrosamine NNK (23) and carbon
monoxide (43) have no detectable effect on
plaque development in vivo. The results pre-
sented here confirm and extend observations
we made previously that, in relation to
plaque development, the active environmen-
tal agents function as promoters (stimulating
development of pre-existing lesions via
repetitive treatment) rather than as initiators
(causing de novo appearance of lesions fol-
lowing a single treatment (10,11,15,16,19,
23,38). The positive control here, the PAH
carcinogen DMBA, which is often used as
an initiator in carcinogenesis studies, did not
elicit appearance of new plaques. Rather, as
in our previous studies (15,16,19,24) it
accelerated development of preexisting
plaques in the most distal portions of the
aorta. The test agent, tar extracted from CS,
containing numerous carcinogens (albeit at
relatively low concentrations), was no more
effective than DMSO, the solvent control,
at stimulating development of aortic
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Figure 2. Effect of repeated injections of cigarette
tar on development of arteriosclerosis. The
means of the log-normally distributed plaque
sizes are shown for cockerels injected weekly
with cigarette tar (TAR), OMBA (positive control),
or DMSO (negative control). The values represent
average total plaque size for the six most distal
aortic segments from cockerels in each group.
For DMBA and TAR, n = 60, and for OMSO, n = 54.
df= 2; F = 4.837; p = 0.009.
Table 2. Comparison of the effect of treatment
with DMBA, cigarette tar (TAR), or DMSO on
plaque size at aortic segments 1 and 3(see Fig. 1)
t-value p-value
Aortic segment#1
(DMBAvs. DMSO) 3.20 0.002
(DMBAvs. TAR) 1.97 0.050
(DMSOvs. TAR) -1.35 0.180
Aortic segment#3
(DMBAvs. DMSO) 2.45 0.015
(DMBA vs. TAR) 2.25 0.026
(DMSO vs. TAR) -0.19 0.851
plaques. Although this distinction between
plaque promoters and initiators is more
functional than mechanistic, a recent mech-
anistic study of the effect of DMBA on
tumor development in mouse epidermis also
emphasized the primary role of DMBA as a
promoter rather than as an initiator of
tumorigenesis (44).
The unfiltered 2R1 cigarettes used both
in this study and in an earlier mainstream
smoke study (38) and the filtered 1R4F
cigarettes used in our recent sidestream
smoke studies (10,11) are standardized
research cigarettes produced by the
Tobacco and Health Research Institute at
the University of Kentucky. Mainstream
smoke tar levels from the 2R1 cigarettes
(33 mg/cigarette) are -3.5 times higher
than those from 1R4F cigarettes (9 mg/cig-
arette). In the earlier 2R1 mainstream
smoke study (38), cockerels inhaled main-
stream smoke 2 hr/day for 16 weeks,
resulting in a moderate but statistically sig-
nificant increase in plaque size. Sidestream
smoke from 1R4F cigarettes has -10%
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more tar than does the mainstream smoke
(13). The lR4F sidestream smoke expo-
sures were 3 times longer (6 hr/day) than
were the earlier 2R1 mainstream smoke
exposures. Thus, the dose x time product
for tar was similar in the two sets ofexpo-
sures. However, the results were not equiv-
alent. Inhalation ofsidestream smoke accel-
erated aortic plaque development far more
than did inhalation ofmainstream smoke.
In the experiments reported here to test
whether the tar fraction of CS promotes
plaque development, the cockerels were
exposed to environmentally relevant levels of
CS tarfraction. When a 2R1 unfiltered ciga-
rette is smoked under standard conditions
(i.e., those specified by the Federal Trade
Commission)-a 35 ml puffof 2 sec dura-
tion, one time per minute, down to a butt
length of 23 mm-the dose to a typical
smoker has been calculated to be 33 mg of
tar. For a one pack per daysmokerweighing
70 kg, the weekly tar dose is 66 mg/kg (33
mg/cigarette x 20 cigarettes x 7 days/70 kg).
This compares favorably with the concen-
trated tar dose administered here-25
mg/kg/week.
The difficulties in demonstrating directly
thatspecific smoke components are responsi-
ble for the respiratory and cardiovascular
health effects of smoking are due in large
part to 1) the extraordinary complexity of
tobacco smoke; 2) the relatively low concen-
tration ofmost ofthe individual components
in the smoke; and 3) the different relative
concentrations of chemicals in mainstream
versus sidestream smoke. For example, B(a)P
levels are -16 times higher in sidestream than
in mainstream smoke of 1R4F cigarettes,
148 ng versus 9 ng (13). However, to pro-
vide B(a)P via inhalation of sidestream
smoke at a level equivalent to the injected
B(a)P level used in our earlier plaque acceler-
ation study, i.e., 40 mg/kg/week(19),
requires the equivalent of nearly 300,000
cigarettes perweekperkgcockerel.
The lower health risks associated with
sidestream versus mainstream smoke are
probably explained by the fact that side-
stream smoke components diffuse through
the air while mainstream smoke compo-
nents are delivered directly to the mouth of
an active smoker. Therefore, the latter
inhales greater amounts of smoke compo-
nents than does a passive smoker.
Nevertheless, the health effects arising from
exposure to ETS, largely discounted until
recently, may be considerable. After deter-
mining ETS exposures in human popula-
tions, assessing lung cancers in humans and
animals exposed to ETS, and evaluating
the association between ETS and lung can-
cer according to its previously established
criteria for causality, the EPA declared that
the highly complex mixture called ETS is
itself a class A human carcinogen (4).
Although the estimate of the number of
excess lung cancers due to ETS exposures
are relatively low, -3,000/year in the
United States (4), the estimated number
of excess heart disease deaths due to ETS
exposure is more than an order of magni-
tude higher (7,45,46). Studies from at
least two laboratories, each using different
animal models, exposure protocols, diets,
and cigarettes as the ETS source, have
shown clearly that ETS inhalation causes
significant augmentation of arteriosclerotic
plaque development (10-12).
With the exception of carbon monox-
ide, a vapor phase component that plays no
direct role in arteriosclerosis in cockerels
(43) and only a small role at best in exacer-
bating other manifestations ofheart disease
in humans (47), investigations of the can-
cer- and arteriosclerosis-associated effects of
CS have long focused on the tar fraction
and its components (25,48,49). Evidence
for activation ofcytochrome P450 enzymes,
which is necessary for the metabolism ofthe
PAH carcinogens, has been reported in the
vascular system following in vivo and in
vitro exposures to carcinogens that are pre-
sent in cigarette tar (22,31,32,50).
However, the concentrations of individual
PAH carcinogens, e.g., B(a)P or 3-methyl-
cholanthrene, needed to activate P450
enzymes in vascular smooth muscle or
endothelial cells are orders of magnitude
higher (17,22,31) than the concentrations
ofthese and related compounds in cigarette
smoke (13). Thus, there is little direct evi-
dence ofa role for environmentally relevant
levels of tar fraction compounds in the
development ofarteriosclerosisis.
Both the experiments described and the
literature reviewed here focus on arte-
riosclerotic plaques and not on lung
tumors; however, the experimental carcino-
genesis literature also raises the question of
whether environmentally relevant levels of
tar fraction components are primarily
responsible for CS-associated carcinogene-
sis. A mid-1960s review and summary of
cigarette tar and carcinogenesis studies dat-
ing back to the early 1900s showed ciga-
rette tar to be largely ineffective as a whole
carcinogen. In addition, the tar was both a
very weak initiator and, at best, only a fair
promoter ofcarcinogenesis (33).
Even more than B(a)P, NNK is regard-
ed as one ofthe most potent carcinogens in
CS (20,21); however, the potency ofNNK
as an experimental lung carcinogen is asso-
ciated with extended exposures, repeated
doses ofmuch higher levels than are found
in cigarettes, or both (14,20,35,51). In
rodent carcinogenesis studies, multiple
NNK doses equivalent to 100-1000 mg/kg
or more have been reported (14,18,35). A
dose of3 mg ofNNK (-15 pmol) is equiv-
alent to the total NNK in the sidestream
smoke from 7,500 1R4F filtered reference
cigarettes or in the mainstream smoke from
37,500 of the same cigarettes (13).
Evidence questioning the role that these
prominent tar fraction carcinogens play in
experimental lung tumor development also
has been provided recently by analysis of
Ki-ras mutation spectra. NNK and PAHs
elicit codon 12, but not codon 61, muta-
tions in Ki-ras, (36,37). However, mice
exposed to sidestream smoke for 6 months
exhibited primarily codon 61 Ki-ras muta-
tions in lung tumors (52).
Finally, another set of recent findings
provides evidence that vapor phase compo-
nents ofCS may represent a greater health
risk than do tar fraction components
(Bombick et al., unpublished data). These
authors tested in vitro cytotoxicity of tar
condensate and filtered smoke, both from
conventional cigarettes and from experi-
mental cigarettes with a charcoal-impreg-
nated filter that selectively removes vapor
phase components from the smoke. The tar
fractions from the two types of cigarettes
did not differ in cytotoxicity; however, the
smoke passing through the experimental
filter was 50% less cytotoxic than smoke
passing through the conventional filters.
The results described here represent the
first clear attempt to affect the course of
arteriosclerotic plaque development in vivo
by direct administration of the tar fraction
of CS. No effect on plaque development
was detected.
This result, combined with recent find-
ings from our laboratory and others, indi-
cates that, at least as far as arteriosclerotic
plaque development is concerned, the CS
components responsible reside in the vapor
phase, not in the tar fraction.
Summaryofthe effect ofcigarette
smoke (CS) and its components on
development ofarteriosderotic
plaque
Experimental data show that inhalation of
either mainstream or sidestream CS at envi-
ronmentally relevant levels results in acceler-
ated arteriosclerotic plaque development in
cockerels (10,11,38). Inhalation of side-
stream CS combined with a high cholesterol
diet also accelerates atherosderosis in rabbits
(12). Epidemiological data show that life
expectancy for ex-smokers approaches that
for nonsmokers as the time since smoking
cessation increases (3). Thus, CS acts as a
promoter ofcardiovascular disease.
The tar fraction ofcigarette smoke con-
tains many carcinogens, including both
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PAH carcinogens and N-nitrosamines, at
very low concentrations (13).
When the PAH carcinogens are delivered
to arterywall cells at high concentrations, the
carcinogens can be activated metabolically by
cytochrome P450 enzymes in the artery wall
(17,22,31,32,48).
If PAH carcinogens are injected into
cockerels at concentrations orders ofmagni-
tude higher than are found in the environ-
ment, accelerated plaque development
results (15,16,19,24). The most prominent
N-nitrosamine in CS, NNK, has no effect
on plaque development after repeated
administration at a moderately high con-
centration (23).
Inhalation of environmentally relevant
levels of 1,3 butadiene, a CS vapor phase
component, accelerates plaque development
in cockerels (23).
Injection of concentrated cigarette tar
has no effect on plaque development in
cockerels.
Thus, we conclude that the arterioscle-
rotic plaque-promoting components ofcig-
arette smoke reside primarily in the vapor
phase.
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NCI Cooperative Breast Cancer Tissue Registry
What is the Registry?
The registry is a collection offormalin-fixed, paraffin-embedded tissues with associated clinical and follow-up data from breast
cancer patients for research studies, particularly those that translate basic research findings to clinical application. Four organi-
zations collaborate to provide a patient base that reflects the local populations offour geographically diverse areas ofthe
United States. Participants include: Fox Chase Cancer Center, Philadelphia, PA; Kaiser Foundation Research Institute, Portland,
OR; University of Miami, Miami, FL; and Washington University, St. Louis, MO. A computerized central database is maintained
in Silver Spring, MD.
What can the Registry provide?
The registry can provide tissue sections from large numbers offormalin-fixed, paraffin-embedded primary breast cancer, pre-
pared, when possible, to meet the requirements ofthe research project. It can provide clinical and outcome data, including
demographic data, diagnosis, extent of disease, treatment, followup, recurrence, survival, and vital status. It cannot identify
patients or provide family history information. Researchers pay for preparation of sections and the costs of shipping. The
Registry does not fund studies. Studies on Registry material may be funded by Federal or non-Federal sources. Documentation
of the availability of Registry materials, in support ofapplications for research funding, may be provided for high-priority
research.
Who can obtain specimens?
Registry specimens and data are available to the entire scientific community for meritorious research studies. The collection is
particularly well suited for validation studies of diagnostic and prognostic markers since it includes primary breast tissue with
associated clinical and outcome data. This valuable finite collection is not intended to support small pilot studies.
How do researchers apply?
Applicants complete brief proposals providing information on the study design and requirements for sample preparation and
clinical and follow-up data. They must document approval for use of human subjects following the requirements ofthe NIH
Office of Protection from Research Risks. Annual application receipt dates are the fifteenth of May, September, andJanuary.
How are requests evaluated?
Requests are evaluated by the Research Evaluation and Decision Panel (REDP), a multidisciplinary, independent panel of
experts that reviews applications for scientific merit and recommends priorities to the Registry Coordinating Committee. The
Coordinating Committee sets operating policies and determines the feasibility of providing tissue for studies.
Can the Registry provide other services?
Additional services such as pathological evaluation (i.e., grading) or clinical information beyond that normally provided may be
available through collaborations with Registry investigators.
Additional information and forms may be obtained from:
Sherrill Long or Margaret Kildee
Information Management Services, Inc.
12501 Prosperity Drive, Suite 200
Silver Spring, MD 20904
Telephone (301) 680-9770
Internetwwwicic.nci.nih.gov/cbctr/index.html
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